Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years

Trial Profile

Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary)
  • Indications Human papillomavirus infections
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 30 Dec 2015 Planned end date changed from 1 Jun 2016 to 1 Jul 2016, as reported by ClinicalTrials.gov.
    • 30 Dec 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2016, as reported by ClinicalTrials.gov.
    • 30 Dec 2015 Status changed from not yet recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top